<sup>131</sup>I治疗青少年及儿童格雷夫斯甲亢的临床应用随访研究

杨凡慧; 陈跃; 张春银; 杨凡慧; 陈跃; 张春银

doi:10.3760/cma.j.issn.1673-4114.2017.02.004

[1]

Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J]. Thyroid, 2011, 21(6):593-646. DOI:10. 1089/thy. 2010. 0417.

[2]

潘中允.实用核医学[M].北京:人民卫生出版社, 2014:177.

Pan ZY. Practice of nuclear medicine[M]. Beijing:People's Medical Publishing House, 2014:177.

[3]

Lavard L, Ranløv I, Perrild H, et al. Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study[J]. Eur J Endocrinol, 1994, 130(6):565-568. doi: 10.1530/eje.0.1300565

[4]

Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood:a National population based study in the UK and Ireland[J]. Clin Endocrinol(Oxf), 2010, 72(3):358-363. DOI:10.1111/j.1365-2265.2009.03717.x.

[5]

Ohye H, Minagawa A, Noh JY, et al. Antithyroid drug treatment for graves' disease in children:a long-term retrospective study at a single institution[J]. Thyroid, 2014, 24(2):200-207. DOI:10.1089/thy.2012.0612.

[6]

Rivkees SA. Pediatric graves' disease:controversies in management[J]. Horm Res Paediatr, 2010, 74(5):305-311. DOI:10. 1159/000320028.

[7]

谭天秩.临床核医学[M]. 2版.北京:人民卫生出版社, 2003:1224.

Tan TZ. Clinice of nuclear medicine[M]. 2nd ed. Beijing:People's Medical Publishing House, 2003:1224.

[8]

陈丹云, 陈棠华. ¹³¹I与抗甲状腺药物治疗儿童Graves病的疗效对照研究[J].中华儿科杂志, 2005, 43(7):507-509. DOI:10.3760/j.issn:0578-1310.2005.07.007.
Chen DY, Chen TH. Comparison of efficacy of ¹³¹I and antithyroid drugs in the treatment of Graves' disease in children[J]. Chin J Pediatr, 2005, 43(7):507-509. doi: 10.3760/j.issn:0578-1310.2005.07.007

[9]

Ma C, Kuang A, Xie J, et al. Radioiodine treatment for pediatric Graves' disease[J/OL]. Cochrane Database Syst Rev, 2008(3):CD006294[2016-11-10]. http://www.ncbi.nlm.nih.gov/pubmed/18646146. DOI:10.1002/14651858.CD006294.pub2.

[10]

郑艳, 赵德善, 付松海, 等.儿童和青少年Graves甲亢患者¹³¹I治疗剂量的分析研究[J].国际放射医学核医学杂志, 2013, 37(2):69-73. doi: 10.3760/cma.j.issn.1673-4114.2013.02.002
Zheng Y, Zhao DS, Fu SH, et al. The dose analysis of ¹³¹I treatment in pediatric patients with Graves hyperthyroidism[J]. Int J Radiat Med Nucl Med, 2013, 37(2):69-73. DOI:10.3760/cma.j.issn.1673-4114.2013.02.002.

[11]

Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive Iodine in treating young Graves' patients[J]. J Clin Endocrinol Metab, 2004, 89(9):4229-4233. DOI:10.1210/jc.2003-031223.

[12]

West JD, Cheetham TD, Dane C, et al. Should radioiodine be the first-line treatment for paediatric Graves' disease?[J]. J Pediatr Endocrinol Metab, 2015, 28(7/8):797-804. DOI:10.1515/jpem-2014-0176.

[1]	Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J]. Thyroid, 2011, 21(6):593-646. DOI:10. 1089/thy. 2010. 0417.
[2]	潘中允.实用核医学[M].北京:人民卫生出版社, 2014:177. Pan ZY. Practice of nuclear medicine[M]. Beijing:People's Medical Publishing House, 2014:177.
[3]	Lavard L, Ranløv I, Perrild H, et al. Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study[J]. Eur J Endocrinol, 1994, 130(6):565-568. doi: 10.1530/eje.0.1300565
[4]	Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood:a National population based study in the UK and Ireland[J]. Clin Endocrinol(Oxf), 2010, 72(3):358-363. DOI:10.1111/j.1365-2265.2009.03717.x.
[5]	Ohye H, Minagawa A, Noh JY, et al. Antithyroid drug treatment for graves' disease in children:a long-term retrospective study at a single institution[J]. Thyroid, 2014, 24(2):200-207. DOI:10.1089/thy.2012.0612.
[6]	Rivkees SA. Pediatric graves' disease:controversies in management[J]. Horm Res Paediatr, 2010, 74(5):305-311. DOI:10. 1159/000320028.
[7]	谭天秩.临床核医学[M]. 2版.北京:人民卫生出版社, 2003:1224. Tan TZ. Clinice of nuclear medicine[M]. 2nd ed. Beijing:People's Medical Publishing House, 2003:1224.
[8]	陈丹云, 陈棠华. ¹³¹I与抗甲状腺药物治疗儿童Graves病的疗效对照研究[J].中华儿科杂志, 2005, 43(7):507-509. DOI:10.3760/j.issn:0578-1310.2005.07.007. Chen DY, Chen TH. Comparison of efficacy of ¹³¹I and antithyroid drugs in the treatment of Graves' disease in children[J]. Chin J Pediatr, 2005, 43(7):507-509. doi: 10.3760/j.issn:0578-1310.2005.07.007
[9]	Ma C, Kuang A, Xie J, et al. Radioiodine treatment for pediatric Graves' disease[J/OL]. Cochrane Database Syst Rev, 2008(3):CD006294[2016-11-10]. http://www.ncbi.nlm.nih.gov/pubmed/18646146. DOI:10.1002/14651858.CD006294.pub2.
[10]	郑艳, 赵德善, 付松海, 等.儿童和青少年Graves甲亢患者¹³¹I治疗剂量的分析研究[J].国际放射医学核医学杂志, 2013, 37(2):69-73. doi: 10.3760/cma.j.issn.1673-4114.2013.02.002 Zheng Y, Zhao DS, Fu SH, et al. The dose analysis of ¹³¹I treatment in pediatric patients with Graves hyperthyroidism[J]. Int J Radiat Med Nucl Med, 2013, 37(2):69-73. DOI:10.3760/cma.j.issn.1673-4114.2013.02.002.
[11]	Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive Iodine in treating young Graves' patients[J]. J Clin Endocrinol Metab, 2004, 89(9):4229-4233. DOI:10.1210/jc.2003-031223.
[12]	West JD, Cheetham TD, Dane C, et al. Should radioiodine be the first-line treatment for paediatric Graves' disease?[J]. J Pediatr Endocrinol Metab, 2015, 28(7/8):797-804. DOI:10.1515/jpem-2014-0176.